DDrare: Database of Drug Development for Rare Diseases

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (2R)-2-Propyloctanoic acid; (6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate; (R)-(-)-2-Propyloctaroic acid; 1.0 MIU IL-2 per day; 2.0 MIU IL-2 per day; 250 mg CK-2017357; 4 cholesten-3-one, oxime; 4-cholesten-3-one, oxime; 40 mg GA; 40 mg glatiramer acetate; 5% glucose water solution; 500 mg CK-2017357; 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one; AB1010; ALPHA-LIPOIC ACID; ALXN1210; ALZT-OP1a (cromolyn); AMSC; AMX0035; ANX005; AP; AP-101; APO-P001; ARIMOCLOMOL; AT-1501; AVP-923; AZILECT® 1 mg Tabletten; Acetate; Acetylcarnitine; Acthar; Actos 15 mg; Actos 30 mg; Actos 45 mg; Albumin; Albutein 5%; Albúmina humana; Amivita; Anakinra; Arimoclomol; Arundic Acid; Arundic acid; AstroRx; Atropine; Autologous Adipose-derived Mesenchymal Stromal Cells; Autologous MSC-NTF cells; Autologous Mesenchymal stem cells (MSCs); Autologous T-regulatory lymphocytes; Autologous adult bone marrow mononuclear cells (BM-MNC) unexpanded; Autologous adult bone marrow mononuclear cells unexpanded; Autologous bone marrow mononucleated cells; Autologous bone marrow-derived stem cells; Autologous mesenchymal stem cells; Azilect; BHV-0223; BIIB050 / KNS-760704; BIIB050/KNS-760704; BIIB067; BIIB067 (ISIS666853); BIIB078; BIIB100; BIIB105; BIOTIN; BLZ945; BOTOX 100 UNITES ALLERGAN (PR1); BOTULINUM TOXIN TYPE A; BRX-345; Baclofen; Basiliximab; Behavioral: BCI-FIT active querying; Behavioral: BCI-FIT adaptive signal modeling; Behavioral: BCI-FIT language modeling; Behavioral: BCI-FIT multi-modal access; Betamethasone; Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days; Biologic: IC14 (monoclonal antibody against human CD14); Biotin; Blood sample and environmental survey; Bosutinib; Botox; Botox injection; Botulinum Toxin Type B; Botulinum toxin type A; Botulinum toxin type B (Myobloc); Butylphthalide; CARBOLITHIUM; CARBOLITHIUM*100CPS 150MG; CBD; CC100; CK-2017357; CK-2017357 (Part A); CK-2017357 (Part B); CK-2127107; CK2017357; CNM-Au8; COLCHICINA; COLCHICINA LIRCA - 1 MG COMPRESSE 60 COMPRESSE; Caffeine; Calogen; Cannabis; Cannabis Sativa extract Oromucosal spray; Cannabis, Medical; Capsaicin; Capsaicin Challenge; Carbidopa; Carbidopa-levodopa; Carbonate; Carbonate de lithium; Ceftriaxone; Celecoxib; Cell-based therapeutics; Cell-based therapy; Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients; Cimetidine; Cimetidine plus Dexpramipexole; Ciprofloxacin; Cistanche Total Glycosides; Clenbuterol; Coenzyme Q10; Colchicina; Colchicine; Colchicine 1 MG Oral Tablet; Combination Product: Active treatment with dual therapy; Control group; Copegus; Copper; Cord blood therapy; Corticotropin; Creatine; Creatine Monohydrate; Creatine monohydrate; Creatinine; Cromolyn; Cu(II)ATSM; Curcumin; Células Mesenquimales de tejido adiposo; Células madre mesenquimales de tejido adiposo autólogo; Células troncales hematopoyéticas autólogas adultas extraidas de médula ósea; DEXMEDETOMIDINE; DEXTRAN SULFATE SODIUM; DNL747; DPA; DaTSCAN; DaTscan; Daraprim; Darunavir; Datscan; Deferiprone; Device: Electrical Impedance Myography; Device: Iowa Oral Performance Instrument; Device: Iowa Oral Pressure Instrument; Device: Micro Mouth Pressure Meter; Device: PowerLung trainer; Device: Pulmonary Function Testing; Device: Stereotactic surgical device; Device: Voluntary Peak Cough Flow Testing; Dexdor; Dexmedetomidine; Dexpramipexole; Dexpramipexole (dose 1); Dexpramipexole (dose 2); Dexpramipexole Dichydrochloride; Dexpramipexole Dihydrochloride; Dextran; Dextran Sodium Sulfur Salt 5, Mw 5 kDa. a type of Low Molecular Weight Dextran Sulfate (LMW-DS); Dextromethorphan; Dextromethorphan HBr and quinidine sulfate; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dolutegravir; Dronabinol; Drug: F 18 T807; Dutasteride; Dutasteride 0.5 mg; E0302 (mecobalamin); EBIXA; EDARAVONE; EH301 (Nicotinamide Riboside/Pterostilbene); EPERISONE; EPI-589; EPREX IV SC 1FL 1ML 40000 UI; EPREX*1SIR 40000UI/ML 1ML; ERYTHROPOIETIN; ESKETAMINE; Edaravone; Endocannabinoid palmitoylethanolamide (PEA); Engensis; Eperisone; Eril®; Erythropoetin (EPO); Erythropoietin; Escitalopram; Esketamine; Ezogabine; FASUDIL HYDROCHLORIDE; FLX-787-ODT; FLX-787-ODT (orally disintigrating tablet); Fasudil; Febuxostat; Fecal microbiota transplantation; Fig; Filgrastim; Fixed dose combination Ciprofloxacin/Celecoxib; Fycompa; G-CSF; GDC-0134; GM604; GSK1223249; GUANA2015; GUANABENZ; GUANABENZ ACETATO; Gilenya; Glatiramer; Glucose; Gold; Gold Nanocrystals; Granulocyte - colony stimulating factor (G-CSF); Granulocyte Colony Stimulating Factor; Growth Hormone (Somatropin); Growth hormone; Guanabenz; HB-adMSCs; HK-001; HUMAN ALBUMIN SOLUTION; HYNR-CS inj; HYNRCS-Allo inj; High-caloric fatty diet; Human Neural Stem Cells; Human albumin; Human autologous mesenchymal stem cells; Hyperpolarized [1-13C]pyruvate; I-123; IBUDILAST; IC14; IL-2; ILB; ILB: 100mg/ml solution for injection and infusion; INTERLEUKIN-2; IPL344; ISIS 333611; Ibudilast; Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy; Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer; Incobotulinum Toxin A; Inosine; Insulin like growth factor, type 1; Interleukin-2; Intra venous injection of stem cell; Intrathecal autologous stem cell; Intrathecal injection; Intravenous administration of 1 million of MSC; Intravenous administration of 2 million of MSC; Intravenous administration of 4 million of MSC; Intraventricular injection; Ioflupane 123I; Isocaloric Diet; Jevity 1.0; Jevity 1.5; KNS-760704; Ketanest; Ketanest-S; KetoCal; L-Serine; LEVOSIMENDAN; LIORESAL*50CPR 10MG; LITHIUM CARBONATE; LITHIUM CITRATE; LITIO CARBONATO; Lacosamide; Lactose; Lenograstim; Leuprolide; Levetiracetam; Levodopa; Levosimendan; Lipoic acid; Lipoic acid group; Liposomed polyphenols resveratrol and curcumin; Lithium; Lithium Apogepha; Lithium Carbonate; Lithium Citrate; Lithium carbonate; Lithium citrate; Lithiumcarbonaat; Lithiumcarbonaat 400 PCH tabletten; Lunasin; Lunasin Regimen; MANNITOLO 18%; MANNITOLO 18% LDB; MASITINIB; MASITINIB MESYLATE; MCI-186; MCI-186 in open label phase; MD1003; MEMANTINE HYDROCHLORIDE; MN-166; MNC (Mononuclear cells); MONITOR; MSC-NTF cells transplantation (IM); MSC-NTF cells transplantation (IT); MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF; MT-1186; MYELOSTIM 34*1FL 263MCG+1SIR; MYONAL*30CPR RIV 100MG; Masitinib; Masitinib (3.0); Masitinib (4.5); Masitinib (6.0); Masitinib 100 mg Tablets; Masitinib 100mg; Masitinib 200 mg Tablets; Masitinib 200mg; Masitinib Mesylate; Masitinib mesylate; Mecobalamin; MediCabilis CBD Oil; Medicine; Memantine; Memantine (Ebixa); Memantine Hydrochloride Oral Solution; Mesenchymal Stromal Cells; Mesenchymal stem cell; Mesenchymal stem cells; Mesenchymal stem cells isolated from Wharton's jelly; Metformin; Methylcobalamin; Methylprednisolone; Mexiletine; Midazolam; Minocycline; Modal; Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections; Moxifloxacin; Multiple Dose; Mycophenolate; Mycophenolate mofetil; Myonal; NP001; NS; Nicotinamide; Nicotinamide riboside; Nuedexta; NurOwn® (MSC-NTF cells); ODM-109; ODM-109 capsule 1 mg; OLANZAPINE; ONO-2506; ONO-2506PO; Olanzapine; Olesoxime; Oral LEVOSIMENDAN; Oral nutritional supplementation; Other:; Other: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; Other: Communicative Effectiveness Survey; Other: Control group; Other: Eating Assessment Tool 10; Other: Eating Assessment Tool-10; Other: Functional Oral Intake Scale; Other: Historical control; Other: Other: Symptomatic treatment of ALS; Other: Saline; Other: Swallowing Quality of Life Questionnaire; Other: Swallowing Related Quality of Life Questionnaire; Other: The Center for Neurologic Studies Bulbar Function Scale; Other: The Center for Neurologic Study Bulbar Function Scale; Oxepa; Ozanezumab; PARACETAMOLO; PBMC autotransplantation; PERFALGAN; PLECONARIL; PLENUR; PU-AD; PYRIMETHAMINE; Palmitoylethanolamide; Pegcetacoplan (APL-2); Perampanel; Phenylbutyrate; Phosphate; Pimozide; Pimozide 2 mg per day; Pimozide 2mg/day (current) or 4 mg/day (study initiation); Pimozide 4 mg per day; Pioglitazone; Pioglitazone and Tretinoin; Plasma from healthy young people treatment + Riluzole; Pleconaril; PolyMVA; Pramipexole; Prednisone; Pridopidine; Probiotic; Procedure: Injection of salivary glands; Procedure: Pulmonary Function Testing; Procedure: Umbilical cord blood therapy; Procedure: Videofluoroscopic Swallowing Study; Procedure: Videofluoroscopic Swallowing Study (VFSS); Procedure: Videofluoroscopic swallowing study; Proleukin; Proleukin 18 MUI; Prototype capsule GDC-0134; Pyrimethamine; Q-Cells; Quinidine; R(+) pramipexole dihydrochloride monohydrate; RAPA-501 Autologous T cells; RAPAMUNE - 1 MG 100 COMPRESSE RIVESTITE IN BLISTER USO ORALE; RASAGILINE MESILATE; RAVULIZUMAB; RETIGABINE; RIBAVIRIN; RILUTEK; RILUTEK 50 mg, film-coated tablets; RILUZOLE; RILUZOLO; RNS60; Rabeprazole; Ranolazine; Ranolazine 1000 MG; Ranolazine 500 MG; Rapamune; Rapamycin; Rasagiline; Rasagiline Mesilate; Ravulizumab; ReQuip CR; Recombinant human erythropoietin(rhEPO); Reference capsule GDC-0134; Reldesemtiv; Repository corticotropin injection; Requip CR tablets; Resveratrol; Retigabine; Ribavirin; Rilutek; Rilutek 50 mg film-coated tablets; Riluzole; Riluzole (100 mg); Riluzole 50 MG; Riluzole 50 MG (Part B); Riluzole Oral Soluble Film; Riluzole Oral Soluble film (ROSF) 50 mg; Ritonavir; SB-509; SNN0029; SNN0029 infusion solution; SODIUM PYRUVATE; SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM; SUB126308; Saline solution; Sativex; Scopolamine; Scopolamine, atropine, edaravone and dexmedetomidine; Selective Serotonin Uptake Inhibitors (SSRI); Serine; Serotonin; Single dose reduced; Single dose standard; Sodium Valproate; Sodium phenylbutyrate; Somatropin; Spirit1; Stem Cell; Stem Cells; Stem cell; Stem cell (HPC) implantation; Sulfate; Suspension of human autologous MSC 3P in 1,5 ml; Suspension of human autologous MSC 3P in 1.5 ml; TAUROURSODEOXYCHOLIC ACID; TCH346; TEVAGRASTIM; TRO19622; TUDCA; TUDCABIL; TV-7110; Tacrolimus; Talampanel; Tallampanel; Tamoxifen; Tamoxifen 40 mg daily for one year; Taurolite; Tauroursodeoxycholic Acid; Tauroursodeoxycholic acid; Tauroursodeoxycholic acid (TUDCA); Tenofovir; Tenofovir alafenamide; Tenofovir alafenamide (TAF); Testosterone; Thalidomide; Thalidomide (drug); Theracurmin HP; Tioctic acid; Tirasemtiv; Tocilizumab; Tocotrienols; Trametinib; Trametinib (0.5 mg); Trametinib (1 mg); Trametinib (2 mg); Trazodone; Trazodone Hydrochloride oral solution; Tretinoin; Tretinoin and Pioglitazone HCL; Tricyclic Antidepressants (TCA); Triheptanoin; Triumeq; Trobalt; Téralithe LP; Ultomiris; Ultra-high-caloric carbohydrate-rich diet; Ultra-high-caloric fatty diet; VM202; Valproate; Verdiperstat; Vitamin E; Water; YAM80; ZIBREN*20BUST 500MG; Zibren; Zilucoplan; Zinc; Zinc and Copper; Zyprexa; [11C]MPC6827; [18F] GE-180; [18F]DPA-714 PET; [18F]PBR06; [I-123] ADAM

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-001862-13-SE (EUCTR)	14/10/2020	23/03/2020	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable	patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na	ABScience	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	495	Phase 3	United States;Portugal;Slovenia;Spain;Ireland;Russian Federation;Israel;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Germany;Netherlands;Sweden
2	NCT03127267 (ClinicalTrials.gov)	October 1, 2020	13/4/2017	Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients	A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: Masitinib (6.0);Drug: Riluzole;Drug: Placebo;Drug: Masitinib (4.5)	AB Science	NULL	Recruiting	18 Years	81 Years	All	495	Phase 3	United States;Germany;Canada
3	EUCTR2019-001862-13-ES (EUCTR)	15/09/2020	12/06/2020	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable	patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na	ABScience	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	495	Phase 3	United States;Portugal;Slovenia;Spain;Ireland;Russian Federation;Israel;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Germany;Netherlands;Sweden
4	EUCTR2019-001862-13-SI (EUCTR)	12/03/2020	19/02/2020	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable	patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na	ABScience	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	495	Phase 3	United States;Portugal;Slovenia;Spain;Ukraine;Ireland;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Germany;Netherlands;Sweden
5	EUCTR2010-024423-24-NL (EUCTR)	21/09/2015	09/09/2015	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel groups, phase 2/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable	patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 19.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na INN or Proposed INN: Masitinib mesylate Other descriptive name: na	ABScience	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 2;Phase 3	Portugal;United States;Serbia;Slovakia;Greece;Spain;Ireland;Colombia;United Kingdom;Italy;France;Czech Republic;Hungary;Mexico;Argentina;Romania;Netherlands;Germany
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2010-024423-24-IT (EUCTR)	05/05/2015	04/02/2014	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	Studio prospettico, multicentrico, randomizzato, in doppio cieco, controllato verso placebo, a gruppi paralleli, di fase 2/3 sull'efficacia e la sicurezza di masitinib a confronto con placebo nel trattamento di pazienti affetti da Sclerosi Laterale Amiotrofica (SLA) - AB10015	patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 18.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Masitinib Product Code: AB1010 INN or Proposed INN: Masitinib Mesylate Other descriptive name: MASITINIB MESYLATE INN or Proposed INN: Masitinib Mesylate Other descriptive name: MASITINIB MESYLATE	AB SCIENCE	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	381		Portugal;Serbia;Slovakia;Greece;Spain;Colombia;Italy;United Kingdom;France;Hungary;Mexico;Argentina;Romania;Germany
7	EUCTR2010-024423-24-HU (EUCTR)	21/04/2015	31/10/2014	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel groups, phase 2/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable	patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 17.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na INN or Proposed INN: Masitinib mesylate Other descriptive name: na	ABScience	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2;Phase 3	Serbia;Portugal;United States;Taiwan;Slovakia;Greece;Spain;Ireland;Israel;Colombia;Italy;United Kingdom;France;Hungary;Czech Republic;Mexico;Argentina;Poland;Belgium;Romania;Netherlands;Germany
8	EUCTR2010-024423-24-PT (EUCTR)	10/04/2015	03/11/2014	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel groups, phase 2/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable	patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		ABScience	NULL	Not Recruiting			Female: yes Male: yes	381	Phase 2;Phase 3	Serbia;Portugal;United States;Slovakia;Greece;Spain;Ireland;Colombia;United Kingdom;Italy;France;Czech Republic;Hungary;Mexico;Argentina;Romania;Netherlands;Germany
9	EUCTR2010-024423-24-GR (EUCTR)	06/03/2015	21/11/2013	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel groups, phase 2/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable	Patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 17.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na	ABScience	NULL	Not Recruiting			Female: yes Male: yes	381	Phase 2;Phase 3	United States;Portugal;Slovakia;Greece;Spain;Ireland;United Kingdom;Italy;France;Czech Republic;Hungary;Argentina;Netherlands;Germany
10	EUCTR2010-024423-24-SK (EUCTR)	07/04/2014	05/12/2013	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel groups, phase 2/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable	patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		ABScience	NULL	Not Recruiting			Female: yes Male: yes	381	Phase 2;Phase 3	Portugal;Serbia;United States;Slovakia;Greece;Spain;Ireland;Colombia;United Kingdom;Italy;France;Czech Republic;Hungary;Mexico;Argentina;Romania;Netherlands;Germany
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	NCT02588677 (ClinicalTrials.gov)	April 2013	20/10/2015	Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)	Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib	Amyotrophic Lateral Sclerosis (ALS)	Drug: Masitinib (4.5);Drug: Riluzole;Drug: Placebo;Drug: Masitinib (3.0)	AB Science	NULL	Completed	18 Years	N/A	All	394	Phase 2;Phase 3	Spain
12	EUCTR2010-024423-24-ES (EUCTR)	29/01/2013	29/11/2012	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable	patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: MASITINIB	ABScience	NULL	Not Recruiting			Female: yes Male: yes	45	Phase 2	Portugal;France;Hungary;Slovakia;Greece;Spain;Ireland;Netherlands;Italy
13	EUCTR2019-001862-13-IE (EUCTR)		04/08/2020	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - AB19001 ALS masitinib/placebo in combination with riluzole	patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Masitinib 100mg Product Code: AB1010 INN or Proposed INN: Masitinib Mesylate Product Name: Masitinib 200mg Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na	AB Science	NULL	NA			Female: yes Male: yes	495	Phase 3	United States;Portugal;Slovenia;Spain;Ireland;Israel;Russian Federation;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Germany;Netherlands;Sweden
14	EUCTR2010-024423-24-IE (EUCTR)		06/11/2014	A controlled clinical study to investigate the effectiveness and safety of the medicine called masitinib when used together with a currently available medicine Riluzole when treating the illness called Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 Study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS). - IRELAND Phase 2/3 study comparing Masitinib/Placebo in ALS	Amyotrophic lateral Sclerosis MedDRA version: 18.0;Level: PT;Classification code 10028003;Term: Motor neurone disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 18.0;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Masitinib 100 mg Tablets Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: SUB126308 Product Name: Masitinib 200 mg Tablets Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: SUB126308	AB Science	NULL	Not Recruiting			Female: yes Male: yes	381	Phase 2;Phase 3	Portugal;United States;Slovakia;Greece;Spain;Ireland;Colombia;Italy;Switzerland;United Kingdom;France;Hungary;Mexico;Argentina;Belgium;Romania;Netherlands;Germany
15	EUCTR2019-001862-13-GB (EUCTR)		24/03/2020	Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)	A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - AB19001 ALS masitinib/placebo in combination with riluzole	patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Masitinib 100mg Product Code: AB1010 INN or Proposed INN: Masitinib Mesylate Other descriptive name: na Product Name: Masitinib 200mg Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na	AB Science	NULL	NA			Female: yes Male: yes	495	Phase 3	United States;Portugal;Slovenia;Spain;Ireland;Russian Federation;Israel;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Germany;Netherlands;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2019-001862-13-SE
(EUCTR)

14/10/2020

23/03/2020

Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable

patients suffering from Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: masitinib
Product Code: AB1010
INN or Proposed INN: Masitinib mesylate
Other descriptive name: na
Product Name: masitinib
Product Code: AB1010
INN or Proposed INN: Masitinib mesylate
Other descriptive name: na

ABScience

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

495

Phase 3

United States;Portugal;Slovenia;Spain;Ireland;Russian Federation;Israel;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Germany;Netherlands;Sweden

NCT03127267
(ClinicalTrials.gov)

October 1, 2020

13/4/2017

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Drug: Masitinib (6.0);Drug: Riluzole;Drug: Placebo;Drug: Masitinib (4.5)

AB Science

NULL

Recruiting

18 Years

81 Years

All

495

Phase 3

United States;Germany;Canada

EUCTR2019-001862-13-ES
(EUCTR)

15/09/2020

12/06/2020

Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

ABScience

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

495

Phase 3

United States;Portugal;Slovenia;Spain;Ireland;Russian Federation;Israel;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Germany;Netherlands;Sweden

EUCTR2019-001862-13-SI
(EUCTR)

12/03/2020

19/02/2020

Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

ABScience

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

495

Phase 3

United States;Portugal;Slovenia;Spain;Ukraine;Ireland;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Germany;Netherlands;Sweden

EUCTR2010-024423-24-NL
(EUCTR)

21/09/2015

09/09/2015

Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel groups, phase 2/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable

patients suffering from Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 19.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: masitinib
Product Code: AB1010
INN or Proposed INN: Masitinib mesylate
Other descriptive name: na
INN or Proposed INN: Masitinib mesylate
Other descriptive name: na
Product Name: masitinib
Product Code: AB1010
INN or Proposed INN: Masitinib mesylate
Other descriptive name: na
INN or Proposed INN: Masitinib mesylate
Other descriptive name: na

ABScience

NULL

Not Recruiting

Female: yes
Male: yes

300

Phase 2;Phase 3

Portugal;United States;Serbia;Slovakia;Greece;Spain;Ireland;Colombia;United Kingdom;Italy;France;Czech Republic;Hungary;Mexico;Argentina;Romania;Netherlands;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2010-024423-24-IT
(EUCTR)

05/05/2015

04/02/2014

Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

Studio prospettico, multicentrico, randomizzato, in doppio cieco, controllato verso placebo, a gruppi paralleli, di fase 2/3 sull'efficacia e la sicurezza di masitinib a confronto con placebo nel trattamento di pazienti affetti da Sclerosi Laterale Amiotrofica (SLA) - AB10015

patients suffering from Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 18.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Masitinib
Product Code: AB1010
INN or Proposed INN: Masitinib Mesylate
Other descriptive name: MASITINIB MESYLATE
INN or Proposed INN: Masitinib Mesylate
Other descriptive name: MASITINIB MESYLATE

AB SCIENCE

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

381

Portugal;Serbia;Slovakia;Greece;Spain;Colombia;Italy;United Kingdom;France;Hungary;Mexico;Argentina;Romania;Germany

EUCTR2010-024423-24-HU
(EUCTR)

21/04/2015

31/10/2014

Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

patients suffering from Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 17.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

ABScience

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 2;Phase 3

Serbia;Portugal;United States;Taiwan;Slovakia;Greece;Spain;Ireland;Israel;Colombia;Italy;United Kingdom;France;Hungary;Czech Republic;Mexico;Argentina;Poland;Belgium;Romania;Netherlands;Germany

EUCTR2010-024423-24-PT
(EUCTR)

10/04/2015

03/11/2014

Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

patients suffering from Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

ABScience

NULL

Not Recruiting

Female: yes
Male: yes

381

Phase 2;Phase 3

Serbia;Portugal;United States;Slovakia;Greece;Spain;Ireland;Colombia;United Kingdom;Italy;France;Czech Republic;Hungary;Mexico;Argentina;Romania;Netherlands;Germany

EUCTR2010-024423-24-GR
(EUCTR)

06/03/2015

21/11/2013

Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

Patients suffering from Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 17.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

ABScience

NULL

Not Recruiting

Female: yes
Male: yes

381

Phase 2;Phase 3

United States;Portugal;Slovakia;Greece;Spain;Ireland;United Kingdom;Italy;France;Czech Republic;Hungary;Argentina;Netherlands;Germany

EUCTR2010-024423-24-SK
(EUCTR)

07/04/2014

05/12/2013

Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

ABScience

NULL

Not Recruiting

Female: yes
Male: yes

381

Phase 2;Phase 3

Portugal;Serbia;United States;Slovakia;Greece;Spain;Ireland;Colombia;United Kingdom;Italy;France;Czech Republic;Hungary;Mexico;Argentina;Romania;Netherlands;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02588677
(ClinicalTrials.gov)

April 2013

20/10/2015

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib

Amyotrophic Lateral Sclerosis (ALS)

Drug: Masitinib (4.5);Drug: Riluzole;Drug: Placebo;Drug: Masitinib (3.0)

AB Science

NULL

Completed

18 Years

N/A

All

394

Phase 2;Phase 3

Spain

EUCTR2010-024423-24-ES
(EUCTR)

29/01/2013

29/11/2012

Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable

patients suffering from Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

ABScience

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Portugal;France;Hungary;Slovakia;Greece;Spain;Ireland;Netherlands;Italy

EUCTR2019-001862-13-IE
(EUCTR)

04/08/2020

Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

Product Name: Masitinib 100mg
Product Code: AB1010
INN or Proposed INN: Masitinib Mesylate
Product Name: Masitinib 200mg
Product Code: AB1010
INN or Proposed INN: Masitinib mesylate
Other descriptive name: na

AB Science

NULL

Female: yes
Male: yes

495

Phase 3

United States;Portugal;Slovenia;Spain;Ireland;Israel;Russian Federation;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Germany;Netherlands;Sweden

EUCTR2010-024423-24-IE
(EUCTR)

06/11/2014

A controlled clinical study to investigate the effectiveness and safety of the medicine called masitinib when used together with a currently available medicine Riluzole when treating the illness called Amyotrophic Lateral Sclerosis (ALS)

A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 Study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS). - IRELAND Phase 2/3 study comparing Masitinib/Placebo in ALS

Amyotrophic lateral Sclerosis
MedDRA version: 18.0;Level: PT;Classification code 10028003;Term: Motor neurone disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 18.0;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Masitinib 100 mg Tablets
Product Code: AB1010
INN or Proposed INN: Masitinib mesylate
Other descriptive name: SUB126308
Product Name: Masitinib 200 mg Tablets
Product Code: AB1010
INN or Proposed INN: Masitinib mesylate
Other descriptive name: SUB126308

AB Science

NULL

Not Recruiting

Female: yes
Male: yes

381

Phase 2;Phase 3

Portugal;United States;Slovakia;Greece;Spain;Ireland;Colombia;Italy;Switzerland;United Kingdom;France;Hungary;Mexico;Argentina;Belgium;Romania;Netherlands;Germany

EUCTR2019-001862-13-GB
(EUCTR)

24/03/2020

Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS)

Product Name: Masitinib 100mg
Product Code: AB1010
INN or Proposed INN: Masitinib Mesylate
Other descriptive name: na
Product Name: Masitinib 200mg
Product Code: AB1010
INN or Proposed INN: Masitinib mesylate
Other descriptive name: na

AB Science

NULL

Female: yes
Male: yes

495

Phase 3

United States;Portugal;Slovenia;Spain;Ireland;Russian Federation;Israel;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Germany;Netherlands;Sweden